🇺🇸 FDA
Patent

US 10202412

β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections

granted A61PA61P31/12

Quick answer

US patent 10202412 (β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections) held by Atea Pharmaceuticals, Inc. expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Atea Pharmaceuticals, Inc.
Grant date
Tue Feb 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P31/12